Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Obinutuzumab in Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT02962401Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Mar 2017
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib and obinutuzumab in Waldenstrom macroglobulinemia (WM), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Progression Free Survival at 8 years. Started Mar 2017; status: completed.
02
Drugs
idelalisibobinutuzumab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02962401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962401.